Increased overall antibiotic susceptibility in Staphylococcus aureus femAB null mutants

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 936-938

  Ling, Baodong ^a,b   Berger Bächi, Brigitte ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; ERYTHROMYCIN; FOSFOMYCIN; LYSOSTAPHIN; METICILLIN; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIUM MUTANT; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

EID: 0344624843     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.936     Document Type: Note

References (14)

1. Alborn, W. E., J. A. Hoskins, S. Unal, J. E. Flokowitsch, C. A. Hayes, J. E. Dotzlaf, W. K. Yeh, and P. L. Skatrud. 1996. Cloning and characterization of femA and femB from Staphylococcus epidermidis. Gene 180:177-181.
2. Baker, C. N., S. A. Stocker, D. H. Culver, and C. Thornsberry. 1991. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J. Clin. Microbiol. 29:533-538.
3. Berger-Bächi, B. 1983. Increase in transduction efficiency of Tn551 mediated by the methicillin resistance marker. J. Bacteriol. 154:533-535.
4. Berger-Bächi, B., A. Strässle, and F. H. Kayser. 1986. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur. J. Clin. Microbiol. 5:697-701.
5. Eady, E. A., J. I. Ross, J. L. Tipper, C. E. Walters, J. H. Cove, and W. C. Noble. 1993. Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. J. Antimicrob. Chemother. 31:211-217.
6. Ehlert, K., W. Schröder, and H. Labischinski. 1997. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation. J. Bacteriol. 179:7573-7576.
7. + antiporter TetA(K) from Staphylococcus aureus. J. Bacteriol. 179:3786-3789.
8. Henze, U., T. Sidow, J. Wecke, H. Labischinski, and B. Berger-Bächi. 1993. Influence of femB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus. J. Bacteriol. 175:1612-1620.
9. Kopp, U., M. Roos, J. Wecke, and H. Labischinski. 1996. Staphylococcal peptidoglycan interpcptide bridge biosynthesis: a novel antistaphylococcal target? Microb. Drug Resist. 2:29-41.
10. Labischinski, H. 1992. Consequences of the interaction of beta-lactam antibiotics with penicillin binding proteins from sensitive and resistant Staphylococcus aureus strains. Med. Microbiol. Immunol. 181:241-265.
11. Maidhof, H., B. Reinicke, P. Blümel, B. Berger-Bächi, and H. Labischinski. 1991. femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains. J. Bacteriol. 173: 3507-3513.
12. Matsuhashi, M., C. P. Dietrich, and J. L. Strominger. 1967. Biosynthesis of the peptidoglycan of bacterial cell walls. The role of soluble ribonucleic acid and of lipid intermediates in glycine incorporation in Staphylococcus aureus. J. Biol. Chem. 242:3191-3206.
13. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. Strandén, A. M., K. Ehlert, H. Labischinski, and B. Berger-Bächi. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:9-16.